Q-omics provides the consensus-scored TRIM73 profile across patient tissues and cancer cell-line models. TRIM73 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRIM73 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TRIM73 RNA expression shows 16,826 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where TRIM73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM73 survival associations across molecular data types. TRIM73 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM73 RNA expression–survival associations across cancer types. High TRIM73 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, CESC, UCEC, BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRIM73 RNA expression.
This table summarizes TRIM73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM73 shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, COAD, KICH and LIHC. The KIRC box plot shows higher TRIM73 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p < 0.001).
This table shows molecular features associated with TRIM73 in patient tissues and cancer cell lines. In patient samples, TRIM73 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM73 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
